Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 5 mechanisms across 5 industry trials with a known mechanism of action.

See full pipeline →

Corticosteroid

1 trials 1 sponsor

Acetylcholine Release Inhibitor

1 trials 1 sponsor

Fluoroquinolone Antibacterial

1 trials 1 sponsor

Quinolone Antimicrobial

1 trials 1 sponsor

Benzodiazepine

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

121 industry-sponsored trials across 67 sponsors

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	Zavicefta, Ceftazidime-Avibactam	—	COMPLETED	2023-08-31	NCT04882085
Iterum Therapeutics, International Limited	Ciprofloxacin	Corticosteroid [EPC]	COMPLETED	2018-07-31	NCT03366207
Xiangbei Welman Pharmaceutical Co., Ltd	Ceftriaxone Sodium and Sulbactam Sodium for Injection	—	COMPLETED	2016-06-11	NCT04066621
Xiangbei Welman Pharmaceutical Co., Ltd	Piperacillin Sodium and Sulbactam Sodium	—	COMPLETED	2016-06	NCT01760109
Johnson & Johnson	doripenem	—	COMPLETED	2011-09-05	NCT00986102
Janssen-Cilag Ltd.,Thailand	Doripenem	—	COMPLETED	2010-07	NCT00965848
Belpharma s.a.	Temocillin	—	WITHDRAWN	2012-11	NCT01543347

Showing 46 of 46 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	Meropenem and Pralurbactam	—	RECRUITING	2026-12	NCT07089186
Valenta Pharm JSC	4-MUST	—	RECRUITING	2027-12-31	NCT07595003
TCM Biotech International Corp.	U101	—	RECRUITING	2028-06-30	NCT07184827
Jiangsu HengRui Medicine Co., Ltd.	HRS-8427	—	RECRUITING	2025-11	NCT06569056
Materia Medica Holding	Raphamin	—	ACTIVE NOT RECRUITING	2026-12-31	NCT06284265
Meiji Seika Pharma Co., Ltd.	co-administration of cefepime and nacubactam	—	COMPLETED	2025-09-01	NCT05905055
GSK	Gepotidacin	—	COMPLETED	2025-03-10	NCT06597344
Spero Therapeutics	TBP-PI-HBr	—	COMPLETED	2025-01-27	NCT06059846
Wockhardt	Cefepime-zidebactam (FEP-ZID)	—	COMPLETED	2024-11-25	NCT04979806
Meiji Seika Pharma Co., Ltd.	co-administration of cefepime and nacubactam	—	COMPLETED	2024-11-22	NCT05887908
GSK	Gepotidacin	—	COMPLETED	2024-02-02	NCT05630833
Iterum Therapeutics, International Limited	Sulopenem etzadroxil/probenecid	—	COMPLETED	2023-11-03	NCT05584657
GSK	Gepotidacin	—	COMPLETED	2022-12-01	NCT04187144
GSK	Gepotidacin	—	COMPLETED	2022-11-30	NCT04020341
Venatorx Pharmaceuticals, Inc.	Cefepime/VNRX-5133 (taniborbactam)	—	COMPLETED	2021-12-14	NCT03840148
Inmunotek S.L.	MV140	—	COMPLETED	2020-11-04	NCT02543827
Spero Therapeutics	TBPM-PI-HBr	—	COMPLETED	2020-05-20	NCT03788967
Sihuan Pharmaceutical Holdings Group Ltd.	Benapenem	—	COMPLETED	2020-05-08	NCT04505683
Allecra	cefepime/AAI101 combination	—	COMPLETED	2020-01-30	NCT03687255
Iterum Therapeutics, International Limited	Sulopenem-Etzadroxil/Probenecid	—	COMPLETED	2020-01-16	NCT03354598
Iterum Therapeutics, International Limited	Sulopenem	—	COMPLETED	2019-12-14	NCT03357614
Shionogi	Cefiderocol	—	COMPLETED	2019-04-01	NCT02714595
Merck	Imipenem+Cilastatin/Relebactam	—	COMPLETED	2018-09-14	NCT03293485
Tetraphase Pharmaceuticals, Inc	Eravacycline	—	COMPLETED	2017-12	NCT03032510
Merck	MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)	—	COMPLETED	2017-09-05	NCT02728089
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Vabomere	—	COMPLETED	2017-07-21	NCT02168946
Bionorica SE	Canephron® N	—	COMPLETED	2017-06	NCT02639520
Venus Remedies Limited	CSE-1034 (Ceftriaxone + Sulbactam + EDTA)	—	COMPLETED	2017-05-08	NCT03477422
Nabriva Therapeutics AG	ZTI-01	—	COMPLETED	2017-01-12	NCT02753946
Achaogen, Inc.	plazomicin	—	COMPLETED	2016-09-22	NCT02486627
Achaogen, Inc.	plazomicin	—	COMPLETED	2016-08-18	NCT01970371
Melinta Therapeutics, Inc.	Meropenem-Vaborbactam	—	COMPLETED	2016-04-28	NCT02166476
Lee's Pharmaceutical Limited	prulifloxacin	—	COMPLETED	2015-03	NCT02439632
Pfizer	Ceftazidime - Avibactam ( CAZ-AVI)	—	COMPLETED	2014-09	NCT01644643
Pfizer	Ceftazidime - Avibactam ( CAZ-AVI)	—	COMPLETED	2014-08	NCT01595438
Pfizer	Ceftazidime - Avibactam ( CAZ-AVI)	—	COMPLETED	2014-08	NCT01599806
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	CXA-201	—	COMPLETED	2013-08-11	NCT01345929
Amneal Pharmaceuticals, LLC	Phenazopyridine Hydrochloride Tables, USP 200 mg	—	COMPLETED	2013-02	NCT01650051
Bionorica SE	Canephron® N	—	COMPLETED	2012-05	NCT01478620
Amneal Pharmaceuticals, LLC	Phenazopyridine Hydrochloride	—	COMPLETED	2010-12	NCT01064024
Merck	ertapenem sodium (MK0826)	—	COMPLETED	2009-02	NCT01014013
AlloVir	Posoleucel (ALVR105)	—	TERMINATED	2024-01-30	NCT04390113
Takeda	Flomoxef	—	TERMINATED	2016-02-02	NCT02302092
Johnson & Johnson	Doripenem	—	TERMINATED	2013-06	NCT01110408
Merck	MK0826 (ertapenem)	—	TERMINATED	2009-06	NCT00771316
Eurofarma Laboratorios S.A.	Norfloxacin	—	WITHDRAWN	2012-10	NCT01527019

Showing 50 of 50 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Locus Biosciences	LBP-EC01 0.1 x IV dose	—	RECRUITING	2026-06	NCT05488340
Vaneltix Pharma, Inc.	VNX001	—	RECRUITING	2026-06	NCT05737121
Vaneltix Pharma, Inc.	VNX001	—	RECRUITING	2026-06	NCT06394830
Valenta Pharm JSC	4-MUST	—	RECRUITING	2026-12-31	NCT06842966
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)	Meropenem-Vaborbactam	—	RECRUITING	2027-01	NCT06672978
GSK	—	—	RECRUITING	2027-05-31	NCT06702449
Ono Pharmaceutical Co., Ltd.	ONO-1110	—	ACTIVE NOT RECRUITING	2026-09	NCT06752603
Shionogi	Cefiderocol	—	COMPLETED	2024-09-17	NCT04215991
AbbVie	BOTOX	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2024-07-05	NCT05141006
KEB Nutraceuticals USA, Inc.	—	—	COMPLETED	2024-06-20	NCT06719115
Enlivex Therapeutics Ltd.	Allocetra-OTS	—	COMPLETED	2024-01-12	NCT04612413
Lipella Pharmaceuticals, Inc.	LP-10	—	COMPLETED	2023-08-21	NCT03129126
Shionogi	Cefiderocol	—	COMPLETED	2023-02-06	NCT04335539
Seikagaku Corporation	SI-722	—	COMPLETED	2021-01-12	NCT04208087
Merck	Ceftolozane/Tazobactam	—	COMPLETED	2020-12-03	NCT03230838
Swisse Wellness Pty Ltd	—	—	COMPLETED	2019-12-31	NCT03042273
Paratek Pharmaceuticals Inc	Omadacycline tablets	—	COMPLETED	2019-05-15	NCT03425396
Astellas Pharma Europe B.V.	ASP6294	—	COMPLETED	2019-03-21	NCT03282318
Lipella Pharmaceuticals, Inc.	LP-08 80mg	—	COMPLETED	2018-06-14	NCT01393223
Entasis Therapeutics	Sulbactam-ETX2514	—	COMPLETED	2018-05-17	NCT03445195
Allecra	Cefepime 1G - 2G / AAI101 0.5G - 0.75G	—	COMPLETED	2018-02-14	NCT03680612
Pfizer	Ceftazidime -avibactam	—	COMPLETED	2017-09-15	NCT02497781
AbbVie	LiRIS®	—	COMPLETED	2017-06-29	NCT02395042
AbbVie	—	—	COMPLETED	2016-10-12	NCT02411110
Shionogi	Cefiderocol	—	COMPLETED	2016-07-26	NCT02321800
Merck	Relebactam 250 mg	—	COMPLETED	2015-07-28	NCT01505634
Aquinox Pharmaceuticals (Canada) Inc.	AQX-1125	—	COMPLETED	2015-06	NCT01882543
MerLion Pharmaceuticals GmbH	Finafloxacin 800 mg i.v. once daily	—	COMPLETED	2014-06	NCT01928433
UroGen Pharma Ltd.	—	—	COMPLETED	2014-04	NCT01997983
Astellas Pharma Europe B.V.	ASP3652	—	COMPLETED	2014-03-18	NCT01613586
Mundipharma Research GmbH & Co KG	Oxycodone naloxone prolonged release tablets	—	COMPLETED	2013-03	NCT01197261
Achaogen, Inc.	levofloxacin	Fluoroquinolone Antibacterial [EPC]	COMPLETED	2012-04-03	NCT01096849
Forest Laboratories	Ceftaroline fosamil and NXL104 (q8h)	—	COMPLETED	2012-03	NCT01281462
Pinnacle Pharmaceuticals, Inc.	PP4001	—	COMPLETED	2011-10	NCT01406587
Watson Pharmaceuticals	2% sodium chondroitin sulfate	—	COMPLETED	2010-12	NCT00919113
Pfizer	NXL104/ceftazidime	—	COMPLETED	2010-06	NCT00690378
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	CXA-101	—	COMPLETED	2010-02-25	NCT00921024
Pfizer	PD 0299685 at 15mg BID	—	COMPLETED	2010-01	NCT00739739
Pfizer	PF-04383119	—	COMPLETED	2009-04-15	NCT00601484
MerLion Pharmaceuticals GmbH	Finafloxacin	Quinolone Antimicrobial [EPC]	COMPLETED	2009-04	NCT00722735
Ironwood Pharmaceuticals, Inc.	IW-3300 rectal foam	—	TERMINATED	2025-01-23	NCT05740007
Adaptive Phage Therapeutics, Inc.	Bacteriophage Therapy	—	TERMINATED	2023-02-28	NCT04287478
Urigen	URG101	—	TERMINATED	2018-05-14	NCT02591199
AbbVie	LiRIS 400 mg	—	TERMINATED	2014-11	NCT01824303
AbbVie	Lidocaine Releasing Intravesical System - LiRIS®	—	TERMINATED	2012-12	NCT01475253
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	JNJ-42160443	—	TERMINATED	2011-06-24	NCT01060254
Pfizer	Tanezumab	—	TERMINATED	2010-11-17	NCT00999518
Xiangbei Welman Pharmaceutical Co., Ltd	High dose	—	SUSPENDED	2022-08-15	NCT01601093
Teva Branded Pharmaceutical Products R&D, Inc.	fremanezumab	—	WITHDRAWN	2022-02-10	NCT04447729
Novartis	LYS228	—	WITHDRAWN	2019-10-28	NCT03377426

Showing 18 of 18 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Valenta Pharm JSC	4-MUST	—	RECRUITING	2027-06-30	NCT07594977
Joincare Pharmaceutical Group Industry Co., Ltd	JKN2501	—	RECRUITING	2026-03-19	NCT07207291
GSK	Gepotidacin	—	NOT YET RECRUITING	2027-08-23	NCT07371429
Imbrium Therapeutics	V117957	—	COMPLETED	2025-01-28	NCT06285214
GSK	GSK3882347	—	COMPLETED	2024-12-03	NCT05138822
GSK	Midazolam	Benzodiazepine [EPC]	COMPLETED	2024-08-13	NCT05760261
GSK	GSK3882347	—	COMPLETED	2021-05-14	NCT04488770
Locus Biosciences	LBP-EC01	—	COMPLETED	2020-11-19	NCT04191148
Sihuan Pharmaceutical Holdings Group Ltd.	benapenem	—	COMPLETED	2019-10-21	NCT04476407
Roche	RO7079901	—	COMPLETED	2017-12-04	NCT03174795
Enox Israel Ltd	—	—	COMPLETED	2015-06	NCT02277171
AbbVie	LiRIS® 400 mg	—	COMPLETED	2014-05	NCT01879683
Trillium Therapeutics Inc.	TTI-1612	—	COMPLETED	2013-02	NCT01559961
AbbVie	LiRIS low dose and LiRIS high dose	—	COMPLETED	2011-09	NCT01150565
Pfizer	tanezumab	—	COMPLETED	2010-09	NCT01030640
Biomedical Development Corporation	Frio Mouth Rinse	—	COMPLETED	2009-06	NCT00801021
Stryker Endoscopy	—	—	TERMINATED	2022-02-08	NCT05006950
Iterum Therapeutics, International Limited	Sulopenem	—	WITHDRAWN	2022-03-25	NCT04700787

Novel Drugs by Company (New molecular entities)

GSK 1 drug

BLUJEPA

GEPOTIDACIN MESYLATE

NDA 2025

MISSION PHARMA 1 drug

LITHOSTAT

ACETOHYDROXAMIC ACID

NDA 1983

ALEMBIC THERAP 1 drug

PIVYA

PIVMECILLINAM HYDROCHLORIDE

NDA 2024

Reformulations (20 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

T5 2010

CEFEPIME IN PLASTIC CONTAINER

Baxter

T3 2008